Cullinan Therapeutics’ (CGEM) Buy Rating Reiterated at BTIG Research

Cullinan Therapeutics (NASDAQ:CGEM)‘s stock had its “buy” rating reissued by equities researchers at BTIG Research in a report released on Friday, Benzinga reports. They currently have a $40.00 price target on the stock. BTIG Research’s price objective points to a potential upside of 170.09% from the company’s previous close.

Other research analysts have also recently issued research reports about the stock. Wedbush upped their price target on shares of Cullinan Therapeutics from $39.00 to $42.00 and gave the stock an “outperform” rating in a report on Thursday, August 13th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cullinan Therapeutics in a report on Wednesday, July 8th. Wall Street Zen cut shares of Cullinan Therapeutics from a “hold” rating to a “sell” rating in a report on Sunday, September 13th. TD Cowen raised Cullinan Therapeutics to a “strong-buy” rating in a research note on Monday, August 24th. Finally, HC Wainwright increased their target price on Cullinan Therapeutics from $30.00 to $35.00 and gave the company a “buy” rating in a research note on Friday. One research analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Cullinan Therapeutics currently has an average rating of “Moderate Buy” and a consensus target price of $33.71.

Cullinan Therapeutics Trading Down 4.1%

Shares of Cullinan Therapeutics stock traded down $0.63 during trading on Friday, hitting $14.81. The stock had a trading volume of 1,715,490 shares, compared to its average volume of 900,974. The firm has a market cap of $953.17 million, a price-to-earnings ratio of -4.78 and a beta of 0.02. Cullinan Therapeutics has a 12 month low of $5.68 and a 12 month high of $23.19. The business’s 50-day moving average is $19.83 and its 200 day moving average is $16.71.

Cullinan Therapeutics (NASDAQ:CGEM) last released its quarterly earnings results on Thursday, August 6th. The company reported ($0.81) earnings per share for the quarter, missing the consensus estimate of ($0.80) by ($0.01). As a group, equities analysts expect that Cullinan Therapeutics will post -3.08 EPS for the current year.

Insider Buying and Selling

In related news, insider Jennifer Michaelson sold 30,000 shares of the stock in a transaction on Thursday, August 13th. The stock was sold at an average price of $20.26, for a total value of $607,800.00. Following the transaction, the insider owned 162,844 shares of the company’s stock, valued at $3,299,219.44. This represents a 15.56% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders sold a total of 46,000 shares of company stock valued at $922,920 over the last quarter. 8.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the company. AlphaCentric Advisors LLC lifted its holdings in Cullinan Therapeutics by 5.7% in the first quarter. AlphaCentric Advisors LLC now owns 20,135 shares of the company’s stock worth $286,000 after buying an additional 1,094 shares during the period. Integrated Wealth Concepts LLC purchased a new stake in Cullinan Therapeutics in the second quarter worth about $25,000. ProShare Advisors LLC lifted its holdings in Cullinan Therapeutics by 15.3% in the fourth quarter. ProShare Advisors LLC now owns 12,489 shares of the company’s stock worth $129,000 after buying an additional 1,661 shares during the period. Allworth Financial LP lifted its holdings in Cullinan Therapeutics by 152.4% in the second quarter. Allworth Financial LP now owns 2,893 shares of the company’s stock worth $53,000 after buying an additional 1,747 shares during the period. Finally, Royal Bank of Canada lifted its holdings in Cullinan Therapeutics by 160.6% in the first quarter. Royal Bank of Canada now owns 4,044 shares of the company’s stock worth $58,000 after buying an additional 2,492 shares during the period. Institutional investors own 86.31% of the company’s stock.

Cullinan Therapeutics News Roundup

Here are the key news stories impacting Cullinan Therapeutics this week:

• Positive Sentiment: BTIG reaffirms a Buy rating and $40 price target. The target implies substantial upside from the recent trading level and indicates that BTIG continues to see significant value in Cullinan’s pipeline. Benzinga analyst rating report
• Positive Sentiment: Multiple clinical readouts are scheduled for the fourth quarter. Cullinan expects multi-dose velinotamig data in systemic lupus erythematosus at the ACR Convergence conference in November, followed by CLN-978 data in lupus, rheumatoid arthritis and Sjögren’s disease, plus updated CLN-049 data in December. These updates could provide important evidence for the company’s T-cell engager strategy. Cullinan fourth-quarter 2026 milestones
• Neutral Sentiment: Reported short interest was effectively zero. Data as of September 24 showed no reported shares sold short and a zero-day short-interest ratio, suggesting that short selling is not a clear explanation for the recent weakness. The figures may also reflect a reporting anomaly and should be interpreted cautiously.
• Negative Sentiment: Cullinan delayed early-stage arthritis-therapy data until December. The postponement removes a near-term catalyst and appears to have disappointed investors, increasing focus on execution and the timing of the company’s immunology programs. Cullinan delays arthritis-therapy data
• Negative Sentiment: Zipalertinib sentiment remains unsettled. Although Phase 3 lung-cancer results were characterized as strong, investors continue to question the drug’s safety profile and the durability of the bull case. Those concerns have overshadowed the efficacy data and contributed to selling pressure. CGEM stock and zipalertinib safety concerns

About Cullinan Therapeutics

Cullinan Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing targeted therapies for cancer and other serious diseases. The company’s approach combines internally developed drug candidates with licensed or acquired programs and partnerships intended to address areas of significant unmet medical need.

Its pipeline has included zipalertinib, an oral tyrosine kinase inhibitor being developed for patients with non-small cell lung cancer whose tumors have EGFR exon 20 insertion mutations.